Recruiting PHASE2/PHASE3 INTERVENTIONAL 1-arm NCT06851663

Trop2-targeted immunoPET Imaging of Solid Tumors

Sponsor: RenJi Hospital

Conditions Bladder Cancer Cervical Cancer Cholangiocarcinoma Endometrial Cancer Head and Neck Cancer Liver Cancer Lung Cancer Nasopharyngeal Cancer Ovarian Cancer Prostate Cancer Solid Carcinoma Solid Tumor Thyroid Cancer Uroepithelial Carcinoma

Interventions [18F]F-RESCA-RT4 [18F]F-RESCA-T4 [68Ga]Ga-NOTA-RT4 [68Ga]Ga-NOTA-T4

Updated 3 times since 2025 Last updated: Dec 2, 2025 Started: Dec 23, 2024 Primary completion: Dec 31, 2027 Completion: Dec 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06851663, this PHASE2/PHASE3 trial focuses on Bladder Cancer and Cervical Cancer and remains actively recruiting participants. Sponsored by RenJi Hospital, it has been updated 3 times since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

3 versions recorded

Jan 2026 — Present [monthly]

Recruiting PHASE2/PHASE3

Phase: NA → PHASE2/PHASE3
May 2025 — Jan 2026 [monthly]

Recruiting NA
Mar 2025 — May 2025 [monthly]

Recruiting NA

First recorded

Dec 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

RenJi Hospital

Data source: RenJi Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China